Increased Siglec-9/Siglec-9L interactions on NK cells predict poor HCC prognosis and present a targetable checkpoint for immunotherapy
Rong Xiao,Ye Tian,Jiwei Zhang,Na Li,Mei Qi,Ling Liu,Jianping Wang,Zhenyu Li,Jie Zhang,Fabao Zhao,Tixiao Wang,Siyu Tan,Chunyang Li,Zhuanchang Wu,Mingyan Yu,Xuemei Jiang,Peng Zhan,Lifen Gao,Bo Han,Xinyong Liu,Xiaohong Liang,Chunhong Ma
DOI: https://doi.org/10.1016/j.jhep.2024.01.028
IF: 25.7
2024-02-08
Journal of Hepatology
Abstract:Background & Aims NK cells are enriched in liver and play critical roles in HCC. NK cell-based anti-HCC therapy is becoming attractive but still rare. Siglec-9 interacts with its ligand (Siglec-9L) and restrains NK cell functions, suggesting it is a potential therapeutic target. However, in situ Siglec-9/Siglec-9L interaction in HCC has not been reported, and a relevant intervention strategy is lacking. Here, we aim to illustrate Siglec-9/Siglec-9L-mediated cell sociology and identify small-molecule inhibitors targeting Siglec-9 to improve NK cell-based HCC immunotherapy. Methods Multiplexed immunofluorescence staining was performed to analyze the expression pattern of Siglec-7, -9 and their ligands in HCC tissues. Then we conducted docking-based virtual screening combined with bio-layer interferometry assays to identify a potent small-molecule Siglec-9 inhibitor. The therapeutic potential was further evaluated in vitro and hepatoma-bearing NCG mice. Results Siglec-9 expression, rather than Siglec-7, was markedly upregulated on tumor-infiltrating NK cells, which correlated significantly with reduced survival of HCC patients. Moreover, the number of Siglec-9L + cells neighboring to Siglec-9 + NK cells was increased in HCC tissues and was also associated with tumor recurrence and short survival, further suggesting Siglec-9/Siglec-9L interaction as a potential therapeutic target. In addition, we identified a small-molecule Siglec-9 inhibitor MTX-3937 which inhibited phosphorylation of Siglec-9 and downstream SHP1 and SHP2. Accordingly, MTX-3937 showed considerable improvement in NK cell functions. Notably, MTX-3937 enhanced cytotoxicity of both human peripheral and tumor-infiltrating NK cells. Furthermore, transfer of MTX-3937-treated NK92 cells greatly suppressed the growth of hepatoma xenografts in NCG mice. Conclusions Our study provides the rationale for HCC treatment by targeting Siglec-9 on NK cells and identifies a promising small-molecule inhibitor against Siglec-9 that enhances NK cell-mediated HCC surveillance.
gastroenterology & hepatology